ESMO 19th World Congress on Gastrointestinal Cancer to Feature Groundbreaking Research

Imedex, LLC to accredit and organise the annual Congress

Barcelona, Spain (PRWEB) April 10, 2017 -- ESMO 19th World Congress on Gastrointestinal Cancer, the premier global event highlighting groundbreaking research and developments in gastrointestinal (GI) malignancies, will be an unprecedented educational experience for 3,500+ healthcare professionals and researchers. Endorsed by leading professional societies and organised by Imedex, a global leader in Oncology education, the event will take place from 28 June to 1 July in Barcelona, Spain.

"The knowledge of GI cancers is growing rapidly and the number of therapeutic options is increasing," said Dr. Eric van Cutsem, Co-Chair of the Congress. "During the ESMO World Congress on Gastrointestinal Cancer, leading experts will discuss the newest data and progress in GI oncology and the ways to integrate this into clinical practice."

There are currently hundreds of ongoing phase III clinical trials, and the field of GI malignancies is continuously evolving. Unleashing new findings, new techniques, and ground breaking research with a focus on a more individualized approach to patient care, the ESMO 19th World Congress on Gastrointestinal Cancer has the potential to change the outcomes of patients with GI malignancies worldwide.

The Scientific Committee, encompassing some of the world’s leading experts in the field of gastrointestinal malignancies, has curated an outstanding list of topics for this year's scientific agenda. Abstracts accepted by the Scientific Committee will be published in a supplement of Annals of Oncology and scheduled for oral or poster presentation. Topics covered by accepted abstracts include malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumors.

“ESMO 19th World Congress on Gastrointestinal Cancer, is a groundbreaking international forum where the world’s brightest minds in the field of gastrointestinal malignancies come together. We invite them to attend and share their research, achievements and best practices for the treatment and care of patients with GI Cancers with the broader healthcare community.”– Dan Lowrie, CEO, Imedex

2017 marks the 19th annual Congress, and will be chaired by Mario Dicato, MD, Eric Van Cutsem, MD, PhD, and Josep Tabernero, MD, PhD. As in the past, the Congress will be certified and organised by Imedex, an industry leader in providing CME programs in live conference settings and online. Attendance is expected to be over 3,500 healthcare professionals and researchers, from 72 different countries.

More Information for Media
Visit www.worldgicancer.com

About Imedex
Imedex is the industry leader in developing and delivering independent, accredited healthcare education. The Company’s programs specialising in oncology, hematology, and gastroenterology are provided through live events around the world as well as through effective online educational opportunities for on-the-go healthcare providers.
Imedex’s high-quality scientific programming translates the latest research into clinically relevant information. Our activities facilitate the needs of time-constrained healthcare professionals who are inundated by information through exceptional organisation and outstanding educational value — all with a proven and sustained impact on patient care.

Imedex provides over 50,000 E-learning experiences annually and its live conferences have welcomed more than 100,000 attendees since 2001. The Company has a global footprint and operates in the United States, Europe, and Asia.

At Imedex, we believe education is the best medicine®. For more information on Imedex and upcoming conferences, visit us online at http://www.imedex.com, on our E-learning Center at http://elc.imedex.com, or via email at registration(at)imedex(dot)com.

About ESMO, European Society for Medical Oncology
ESMO is the leading European professional organisation for medical oncology. Comprising more than 15,000 oncology professionals from over 130 countries, we are the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.

Founded in 1975, ESMO has European roots and a global reach: we welcome oncology professionals from around the world. We are a home for all oncology stakeholders, connecting professionals with diverse expertise and experience. Our educational and information resources support an integrated, multi-professional approach to cancer treatment. We seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide. www.esmo.org

About Annals of Oncology
Annals of Oncology is a monthly journal published on behalf of the European Society for Medical Oncology (ESMO) by Oxford Journals. Professor Jean-Charles Soria is editor-in-chief.
http://annonc.oxfordjournals.org/

About the Congress Chairs
Mario Dicato, MD
Congress Chair
Head of Internal Medicine and the Division of Hematology and Oncology
Luxembourg Medical Center
Head, Research Laboratory
Luxembourg Foundation for Research on Cancer and Blood Diseases
Luxembourg, Luxembourg

Eric Van Cutsem, MD, PhD
Congress Chair
Professor of Internal Medicine
University of Leuven
Head, Digestive Oncology Unit
University Hospital Gasthuisberg
Leuven, Belgium
Josep Tabernero, MD, PhD
Congress Vice Chair
ESMO President-elect
Head, Medical Oncology Department
Vall d’Hebron University Hospital
Director of the Vall d’Hebron Institute of Oncology
Barcelona, Spain
Contact Information
Brandee Plott
Imedex
http://www.imedex.com
+1 (720) 238-2911

Online Web 2.0 Version
You can read the online version of this press release here.

If you have any questions regarding information in these press releases please contact the company listed in the press release. Our complete disclaimer appears here - PRWeb ebooks - Another online visibility tool from PRWeb.